EMA panel recommends extending use of AbbVie's Skyrizi drug to treat Crohn's disease

Sep. 16, 2022 9:47 AM ETAbbVie Inc. (ABBV)By: Anuron Mitra, SA News Editor3 Comments

Abbvie

vzphotos

  • The European Union drug regulator's human medicines committee has recommended extending the indication for AbbVie's (NYSE:ABBV) psoriasis and arthritis drug Skyrizi, according to the highlights of their latest meeting released on Friday.
  • The European Medicines Agency's Committee for

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.